Nom du produit:(2,6-Dimethylphenyl)(oxazol-2-yl)methanone
IUPAC Name:2-(2,6-dimethylbenzoyl)-1,3-oxazole
| Unité d'emballage | Stock disponible | Prix($) | Quantité |
|---|---|---|---|
| CM322352-1g | in stock | ƎƎư |
|
|
|||
| Product Overview |
(2,6-Dimethylphenyl)(oxazol-2-yl)methanone, commonly known as DMO, is a synthetic compound that has gained significant attention in the field of medicinal chemistry. It belongs to the oxazole family and is known for its potential applications as a drug candidate. |
| Synthesis and Application |
The synthesis of DMO involves the reaction of 2,6-dimethylphenyl hydrazine and ethyl oxalyl chloride in the presence of triethylamine. The resulting compound is then subjected to a cyclization reaction to form DMO. The purity and yield of DMO can be improved by using different purification techniques such as column chromatography, recrystallization, and distillation. DMO has been extensively studied for its potential use as a drug candidate. It has been found to exhibit various pharmacological activities such as anti-inflammatory, analgesic, anticonvulsant, and antitumor effects. DMO has also been investigated for its potential use in the treatment of Alzheimer's disease, Parkinson's disease, and other neurological disorders. |
| Future Directions |
There are several future directions for DMO. One potential area of research is the development of novel DMO derivatives with improved pharmacological properties. Another area of research is the investigation of the potential use of DMO in combination with other drugs to enhance its therapeutic effects. Additionally, further studies are needed to elucidate the exact mechanism of action of DMO and its potential use in the treatment of various neurological disorders. |
Recherche 
+86 21 5895 0110 
